Who is sponsoring KHAD?

KHAD is sponsored by Beth Israel Deaconess Medical Center.

What drugs are being tested in KHAD?

Interventions: Ketoconazole, Hydrocortisone and Dutasteride.

Last reviewed 2015-04-20 · How we verify

A Phase II Trial of Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer (KHAD)

NCT00673127 Phase 2 COMPLETED Results posted

The combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. The purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will make the combination more effective in treating prostate cancer.

Details

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 2
Status	COMPLETED
Enrolment	57
Start date	2005-02
Completion	2012-12

Conditions

Prostate Cancer

Interventions

Ketoconazole, Hydrocortisone and Dutasteride

Primary outcomes

PSA Response — From treatment initiation until treatment cessation. Maximum 32 months. Median treament duration 8 months.
PSA decline of 50% from baseline confirmed by a PSA at least 4 weeks later.

Countries

United States, Canada